Anti-CD28 antibody [CB28] - BSA and Azide free

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

CD28 also known as T-cell-specific surface glycoprotein CD28 or TP44 plays an important role as a co-stimulatory receptor on T cells. This glycoprotein has a molecular mass of about 44 kDa and is located mainly on the cell surface of T cells. CD28 expression also occurs on thymocytes and some B cells. It forms part of the immunoglobulin superfamily featuring in significant antibody interactions. Researchers often use anti-CD28 antibodies for various immunological assays including CD28 ELISA to study its function.

Biological function summary

CD28 co-stimulates T cells after antigen presentation. It enhances T cell proliferation survival and cytokine production. CD28 functions alongside the T cell receptor (TCR) complex mediating signals that promote full T cell activation. This interaction amplifies the immune response forming an important axis of immune system communication. CD28 interacts with its ligands B7-1 (CD80) and B7-2 (CD86) found on antigen-presenting cells (APCs) illustrating its role in immune system dynamics.

Pathways

CD28 is integral to the PI3K/Akt and MAPK/ERK signaling pathways. These pathways conduct signals critical for cellular growth and survival linking CD28 to downstream transcription factors. The interaction with another protein CTLA-4 acts as a regulatory balance for CD28 signaling preventing over-activation of T cells. This balance influences immune homeostasis and tolerance providing a framework for understanding costimulatory and inhibitory signaling.

Associated diseases and disorders

CD28's role becomes evident in autoimmune diseases and transplant rejection. Abnormal CD28 signaling links to rheumatoid arthritis where inappropriate T cell activation occurs. Similarly CD28 activity contributes to organ transplant rejection by stimulating T cell-mediated responses against transplanted tissues. CTLA-4 through regulatory feedback can modify these effects providing therapeutic target strategies for managing such disorders. Efforts to modulate CD28 activity involve developing therapeutic agents such as anti-CD28 monoclonal antibodies.